Roche: FDA Accepts Fenebrutinib Application For Priority Review In Relapsing And Primary Progressive Multiple Sclerosis

First BTK Inhibitor To Receive FDA Filing Acceptance For Both Forms Of MS - Reduced Relapses By 51% And 58% Versus Teriflunomide In Phase III Relapsing MS Trials - Slowed Disability Progression Versus Ocrevus In Phase III Primary Progressive MS Trial